JP2018522579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522579A5 JP2018522579A5 JP2018512825A JP2018512825A JP2018522579A5 JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5 JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- supernatant
- cell culture
- level
- vitro cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158571A JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164367P | 2015-05-20 | 2015-05-20 | |
| US62/164,367 | 2015-05-20 | ||
| US201662320032P | 2016-04-08 | 2016-04-08 | |
| US62/320,032 | 2016-04-08 | ||
| PCT/US2016/033187 WO2016187378A1 (en) | 2015-05-20 | 2016-05-19 | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Division JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522579A JP2018522579A (ja) | 2018-08-16 |
| JP2018522579A5 true JP2018522579A5 (enExample) | 2019-06-27 |
Family
ID=57320751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512825A Pending JP2018522579A (ja) | 2015-05-20 | 2016-05-19 | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10548976B2 (enExample) |
| EP (2) | EP4190805A3 (enExample) |
| JP (2) | JP2018522579A (enExample) |
| CN (1) | CN108350057A (enExample) |
| CA (1) | CA2986432A1 (enExample) |
| HK (1) | HK1252174A1 (enExample) |
| MA (1) | MA42160A (enExample) |
| WO (1) | WO2016187378A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| EP3370754A4 (en) * | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2018128080A1 (ja) * | 2017-01-06 | 2018-07-12 | オリンパス株式会社 | 細胞観察システム |
| KR20250059538A (ko) * | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| AU2021263760A1 (en) * | 2020-04-28 | 2022-11-24 | Acceleron Pharma Inc. | ActRII proteins and use in treating post-capillary pulmonary hypertension |
| US20230226146A1 (en) * | 2020-06-23 | 2023-07-20 | Acceleron Pharma Inc. | Actrii proteins for the treatment of pulmonary arterial hypertension (pah) |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4240399A4 (en) * | 2020-11-06 | 2024-10-09 | Acceleron Pharma Inc. | FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01007820A (es) | 1999-02-04 | 2003-06-19 | Technion Res & Dev Foundation | Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras. |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| KR101871510B1 (ko) | 2008-06-26 | 2018-06-26 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| CA2770822C (en) | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| ES2613523T3 (es) | 2009-09-09 | 2017-05-24 | Acceleron Pharma, Inc. | Antagonistas de ActRIIb y dosificación y usos de los mismos |
| US20110129469A1 (en) | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| EP3520805B1 (en) * | 2011-10-17 | 2021-03-10 | Acceleron Pharma Inc. | Compositions for treating myelofibrosis |
| JP6401172B2 (ja) | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| MX388380B (es) | 2014-04-18 | 2025-03-19 | Acceleron Pharma Inc | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| WO2016183280A1 (en) | 2015-05-13 | 2016-11-17 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| RU2748278C2 (ru) | 2016-07-15 | 2021-05-21 | Акселерон Фарма Инк. | Композиции и способы лечения легочной гипертензии |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| SMT202400437T1 (it) | 2017-06-14 | 2024-11-15 | Celgene Corp | Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia |
-
2016
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 CA CA2986432A patent/CA2986432A1/en active Pending
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 HK HK18111575.0A patent/HK1252174A1/zh unknown
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/en not_active Withdrawn
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/en not_active Withdrawn
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/en not_active Ceased
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522579A5 (enExample) | ||
| US12286477B2 (en) | Anti-TCR antibody molecules and uses thereof | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Madonna et al. | The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis | |
| US10808009B2 (en) | Peptide conjugates | |
| ES2900233T3 (es) | Moléculas que se unen a CD70 y métodos de uso de las mismas | |
| Acharya et al. | Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate West Nile virus clearance | |
| Deckers et al. | Innate immune cells in asthma | |
| US20230197187A1 (en) | Selective peptide antagonists | |
| JP2018184428A5 (enExample) | ||
| AU2016313107A1 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
| JP2021534823A (ja) | 抗ｂｃｍａ単一ドメイン抗体及びその適用 | |
| KR20240004462A (ko) | Tcr에 결합하는 다기능성 분자 및 이의 용도 | |
| Paroli et al. | The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment | |
| CN120943971A (zh) | 用于刺激自然杀伤细胞的组合物和方法 | |
| JP2020512284A5 (enExample) | ||
| Musiu et al. | Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis | |
| Lamers et al. | Brain-specific HIV Nef identified in multiple patients with neurological disease | |
| CN118414355A (zh) | 抑制小胶质细胞活化的方法 | |
| Zhang et al. | Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment | |
| Tristán-Manzano et al. | Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells | |
| Steele et al. | The metabolic reprogramming of T cells controls airway remodeling in severe asthma | |
| WO2024259186A2 (en) | Cd74 car-t therapy and methods of use thereof | |
| Di Padova et al. | IL-17A family, receptors, proinflammatory effects, and production |